Glass House Brands (GLAS) Share-based Compensation (IS) (2021 - 2024)
Glass House Brands (GLAS) posted quarterly Share-based Compensation (IS) of $345000.0 for Q1 2024, up 189.92% quarter-over-quarter from $119000.0 in Q4 2023.
Glass House Brands (GLAS) Share-based Compensation (IS) (2021 - 2024) Analysis & Trends
Glass House Brands (GLAS) has reported Share-based Compensation (IS) for 4 consecutive years, with $345000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Share-based Compensation (IS) changed N/A year-over-year to $345000.0; the TTM figure through Mar 2024 stood at $729000.0 (changed N/A YoY), while the FY2023 annual figure was $119000.0, changed N/A from the prior year.
- Share-based Compensation (IS) climbed to $345000.0 in Q1 2024 per GLAS's latest filing, from $119000.0 in the prior quarter.
- Across five years, Share-based Compensation (IS) topped out at $345000.0 in Q1 2024 and bottomed at $69000.0 in Q1 2022.
- Historically, Share-based Compensation (IS) has averaged $174833.3 across 4 years, with a median of $146000.0 in 2021.
- On a YoY basis, Share-based Compensation (IS) climbed as much as 63.35% in 2022 and fell as far as 63.35% in 2022.
- Glass House Brands' Share-based Compensation (IS) stood at $173000.0 in 2021, then tumbled by 46.82% to $92000.0 in 2022, then rose by 29.35% to $119000.0 in 2023, then jumped by 189.92% to $345000.0 in 2024.
- Business Quant data shows GLAS's Share-based Compensation (IS) at $345000.0 in Q1 2024, $119000.0 in Q4 2023, and $92000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (IS) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.67 Bn | 17.78 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Glass House Brands | 830.21 Mn | 811.66 Mn | 15.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 345,000.00 |
| Mar 31, 2024 | 345,000.00 |
| Dec 31, 2023 | 119,000.00 |
| Dec 31, 2023 | 119,000.00 |
| Jun 30, 2022 | 92,000.00 |
| Jun 30, 2022 | 92,000.00 |
| Mar 31, 2022 | 69,000.00 |
| Mar 31, 2022 | 69,000.00 |
| Sep 30, 2021 | 173,000.00 |
| Sep 30, 2021 | 173,000.00 |
| Jun 30, 2021 | 251,000.00 |
| Jun 30, 2021 | 251,000.00 |